Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    Austria Belgium Denmark France Germany Italy +4
  • A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Belgium Denmark France Germany Italy The Netherlands +2
  • Study of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Austria Belgium Bulgaria Czechia Denmark Estonia +12
  • A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Belgium Czechia France Germany Hungary Italy +2
  • Comparing irinotecan plus cetuximab with trifluridine and tipiracil plus bevacizumab for patients with metastatic colorectal cancer as third line treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Italy
  • Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    France
  • Study of encorafenib and cetuximab treatment for patients with BRAF V600E-mutant metastatic colorectal cancer who previously responded to BRAF inhibitor therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain
  • Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Czechia Germany Italy The Netherlands Spain
  • Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

    Recruiting

    2 1 1 1
    France Germany Italy Spain
  • Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

    Recruiting

    3 1 1 1
    Finland France Germany Hungary Italy The Netherlands +3